Prospective Comparison of Cirrus Versus Stratus Ocular Coherence Tomography for Different Retinal Pathology.

• Sponsor: University of Chicago (Other)
• Overall Status: Completed
• CT.gov ID: NCT00731458
• Collaborator: Research to Prevent Blindness (Other)
• Enrollment: 60
• Duration (Months): 6

Study Details

Study Description

Brief Summary

Ocular Coherence Tomography (OCT) is a non-invasive ophthalmologic test that uses reflected, unheated, non-concentrated visible light in order to scan and provide a 2-dimensional topographic analysis of the retina and optic nerve. It has wide diagnostic utility especially in patients with clinically significant macular edema, glaucoma, and other retinal eye diseases. At the University of Chicago, we have utilized the Stratus brand OCT (Carl Zeiss Inc) for the past 5 years. Recently we have acquired a beta version of the company's new model, the Cirrus HD-OCT (Carl Zeiss Inc.) which features improved resolution, shorter scanning time and a more user-friendly interface. The purpose of this study is to compare findings between the two models in patients with different common and uncommon eye diseases, including diabetic macular edema, glaucoma and age-related macular degeneration. We hypothesis that the Cirrus OCT is able to accurately quantify eye pathology compared to Stratus OCT.

Condition or Disease	Intervention/Treatment	Phase
Retinal Pathology	Device: Optical coherance tomography ( Cirrus; Stratus)	N/A

Study Design

• Study Type: Interventional
• Actual Enrollment: 60 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Health Services Research
• Official Title: Prospective Comparison of Cirrus and Stratus Optical Coherence Tomography for Quantifying Retinal Thickness
• Study Start Date: May 1, 2007
• Actual Primary Completion Date: Nov 1, 2007
• Actual Study Completion Date: Nov 1, 2007

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Any eye pathology that may cause macular edema.

Exclusion Criteria:

• Vitreous media opacities including dense cataracts, vitreous hemorrhage, and corneal opacities

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• University of Chicago
• Research to Prevent Blindness

Investigators

• Principal Investigator: Seenu Hariprasad, M.D., University of Chicago

Study Documents (Full-Text)

None provided.

More Information

Publications

• Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci. 2008 Oct;49(10):4290-6. doi: 10.1167/iovs.08-2113. Epub 2008 May 30.
• Gupta V, Gupta P, Singh R, Dogra MR, Gupta A. Spectral-domain Cirrus high-definition optical coherence tomography is better than time-domain Stratus optical coherence tomography for evaluation of macular pathologic features in uveitis. Am J Ophthalmol. 2008 Jun;145(6):1018-1022. doi: 10.1016/j.ajo.2008.01.021. Epub 2008 Mar 17.

• Responsible Party: University of Chicago
• ClinicalTrials.gov Identifier: NCT00731458
• Other Study ID Numbers: 15606B
• First Posted: Aug 11, 2008
• Last Update Posted: Sep 5, 2013
• Last Verified: Sep 1, 2013

• Keywords provided by University of Chicago: OCT;; Cirrus;; Stratus;; macular thickness

Study Results

No Results Posted as of Sep 5, 2013